Abstract
New problems are emerging in the health sector as the global Coronavirus Disease 2019 (COVID-19) pandemic expands worldwide. The big global emergency is the need for effective testing tools, therapies, and vaccines for COVID-19. Although these targets are particularly important, the increasing risk of coinfections is a significant threat to health systems and patients’ lives. Although statistical data are still not adequately released, coinfections in patients with COVID-19 developed secondary systemic mycosis. Any of these significant results will be discussed in this review with the main objective of warning the population of the high risk of concomitant systemic mycosis in individuals with COVID-19 induced weakness.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
